Forsteo Is the First Bone Formation Agent Approved for Marketing Across All Member States of The European Union Lilly (NYSE:LLY) announced today that the European Commission has granted a marketing ...
Regulators in Europe have given the go-ahead to a new indication for Eli Lilly’s blockbuster Forsteo. Regulators in Europe have given the go-ahead to a new indication for Eli Lilly’s blockbuster ...
Eli Lilly gibt bekannt, dass das Medikament Forsteo zur Behandlung einer bestehenden Osteoporose bei Frauen in der Postmenopause mit einem hohen Risiko für Knochenbrüche nun in den 15 Mitgliedsländern ...
Two biosimilars of Eli Lilly’s blockbuster osteoporosis treatment Forsteo – from Hungary’s Gedeon Richter and German partner Stada – have made their debut in Europe. Forsteo (teriparatide) – a ...
Both products are approved in adults for osteoporosis in various indications. Richter has announced the launch of Terrosa (teriparatide) in Europe, a biosimilar of Eli Lilly’s Forsteo (teriparatide).
Many younger women suffering osteoporosis could miss out on vital drugs under new guidance for the NHS, campaigners have warned. The National Osteoporosis Society (NOS) said some women with fragile ...
Eli Lilly and Company (NYSE: LLY) meldete heute, dass der Ausschuss für Humanarzneimittel (CHMP) der Europäischen Agentur für die Beurteilung von Arzneimitteln (EMEA) eine positive Einschätzung mit ...
Thousands of women crippled by osteoporosis could benefit from the first drug to rebuild their bones. Tests show Forsteo cuts the risk of spinal fractures by 90 per cent and halves the chances of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results